Pre-made Ocrelizumab biosimilar ( Whole mAb, anti-MS4A1 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-389
Anti-MS4A1 therapeutic antibody (Pre-made Ocrelizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Ocrelizumab, sold under the brand name Ocrevus, is a pharmaceutical drug for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-MS4A1 therapeutic antibody (Pre-made Ocrelizumab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Approved|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||4k7p:YX|
|Companies||Biogen;Biogen Idec;Chugai Pharmaceutical;Genentech;Roche|
|Conditions Approved||Multiple sclerosis|
|Conditions Discontinued||Eye disorders;Haematological malignancies;Lupus nephritis;Rheumatoid arthritis;Systemic lupus erythematosus|